Human antibodies against Mycobacterium avium ssp. paratuberculosis combined with cytokine levels for the diagnosis and selection of Crohn’s disease patients for anti-mycobacterial therapy—A pilot study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0308911 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von J Todd Kuenstner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biology Department, Abilene Christian University, Abilene, Texas, United States of America. Hauptthemen laut MEDLINE: Crohn Disease, Mycobacterium avium subsp. paratuberculosis, Cytokines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Increasing evidence links a worldwide bacterial infection of cattle and other animal species by Mycobacterium avium ssp. paratuberculosis (MAP) to Crohn’s disease (CD). A large, FDA phase 2/3 controlled clinical trial of combination antimycobacterial antibiotic therapy for CD has been completed, and the report describing the trial is pending publication. The identification of MAP infection in CD patients will become increasingly important. Thus, it is desirable to develop MAP-based tests that accurately predict which CD patients have a MAP infection. A prospective, case-control laboratory test study of 199 subjects (61 CD patients and 138 non-CD controls) was performed using a panel of MAP antigens, including Hsp65, PknG, PtpA, CL1, and MAP IDEXX, which were measured under blind conditions in the plasma of the 199 subjects. Results showed that compared to any individual MAP antigen, combinations of antigens showed improved CD classification performance. For the Hsp65 antigen, the sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV), correct classification (CC), and area under the curve (AUC) were 59.02%, 58.70%, 38.71%, 76.42%, 59.3% and 0.606, respectively. For the best combination of MAP antibodies (Hsp65 and PknG), the SEN, SPE, PPV, NPV, CC, and AUC were 59.02%, 60.87%, 40.00%, 77.06%, 60.30%, and 0.631, respectively. Further improvement of the CD classification performance was achieved by combining IFN-γ, IL-8, and IL-17 cytokines with antibodies against MAP antigens, yielding SEN, SPE, PPV, NPV, CC, and AUC of 62.3%, 62.32%, 42.22%, 78.9%, 62.31% and 0.708, respectively. Thus, combinations of antibodies against MAP antigens and cytokine levels yield better CD diagnostic predictive performance than any individual antibodies against MAP antigens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biology Department, Abilene Christian University, Abilene, Texas, United States of America.
- PZM Diagnostics, Charleston, West Virginia, United States of America.
- Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States of America.
- Sport Injury Prevention Research Centre, University of Calgary, Calgary, Alberta, Canada.
- Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
ORCID-Profile: Jean-Michel Galarneau, Horacio Bach
Zitieren
APA
Kuenstner, J. T., Zhang, P., Potula, R., Galarneau, J. M., & Bach, H. (2024). Human antibodies against Mycobacterium avium ssp. paratuberculosis combined with cytokine levels for the diagnosis and selection of Crohn’s disease patients for anti-mycobacterial therapy—A pilot study. PLOS ONE. https://doi.org/10.1371/journal.pone.0308911
Vancouver
Kuenstner JT, Zhang P, Potula R, Galarneau JM, Bach H. Human antibodies against Mycobacterium avium ssp. paratuberculosis combined with cytokine levels for the diagnosis and selection of Crohn’s disease patients for anti-mycobacterial therapy—A pilot study. PLOS ONE. 2024. doi:10.1371/journal.pone.0308911
BibTeX
@article{Kuenstner2024,
author = {Kuenstner, J Todd and Zhang, Peilin and Potula, Raghava and Galarneau, Jean-Michel and Bach, Horacio},
title = {Human antibodies against Mycobacterium avium ssp. paratuberculosis combined with cytokine levels for the diagnosis and selection of Crohn’s disease patients for anti-mycobacterial therapy—A pilot study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0308911}
}
EUVIMED